DK1802625T3 - Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer - Google Patents

Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer

Info

Publication number: DK1802625T3
Authority: DK; Denmark
Prior art keywords: cdk2; angiogenesis; colon; breast; lung
Prior art date: 2004-10-13

Application number

DK05792946T

Other languages

Danish (da)

Inventor

Giacomo Pizzolato

Yi Ren

Kshitij Chhabilbhai Thakkar

Peter Michael Wovkulich

Zhuming Zhang

Jin-Jun Liu

Kin-Chun Luk

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-13

Filing date

2005-10-04

Publication date

2008-09-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1802625(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-04 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-09-01 Application granted granted Critical

2008-09-01 Publication of DK1802625T3 publication Critical patent/DK1802625T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK05792946T 2004-10-13 2005-10-04 Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer DK1802625T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61817404P	2004-10-13	2004-10-13
PCT/EP2005/010653 WO2006040036A1 (en)	2004-10-13	2005-10-04	Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer

Publications (1)

Publication Number	Publication Date
DK1802625T3 true DK1802625T3 (en)	2008-09-01

Family

ID=35311946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05792946T DK1802625T3 (en)	2004-10-13	2005-10-04	Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer

Country Status (26)

Country	Link
US (1)	US7524840B2 (en)
EP (1)	EP1802625B1 (en)
JP (1)	JP2008515939A (en)
KR (1)	KR100858262B1 (en)
CN (2)	CN101039946B (en)
AR (1)	AR051326A1 (en)
AT (1)	ATE398619T1 (en)
AU (1)	AU2005293818A1 (en)
BR (1)	BRPI0518152A (en)
CA (1)	CA2582985A1 (en)
DE (1)	DE602005007623D1 (en)
DK (1)	DK1802625T3 (en)
ES (1)	ES2308551T3 (en)
HK (1)	HK1108284A1 (en)
HR (1)	HRP20080429T3 (en)
IL (1)	IL182423A0 (en)
MX (1)	MX2007004464A (en)
NO (1)	NO20071794L (en)
NZ (1)	NZ554353A (en)
PL (1)	PL1802625T3 (en)
PT (1)	PT1802625E (en)
RU (1)	RU2394826C2 (en)
SI (1)	SI1802625T1 (en)
TW (1)	TWI309652B (en)
WO (1)	WO2006040036A1 (en)
ZA (1)	ZA200702973B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2270014A1 (en)	2005-09-22	2011-01-05	Incyte Corporation	Azepine inhibitors of janus kinases
BRPI0617252A2 (en) *	2005-10-14	2011-07-19	Hoffmann La Roche	administration regimen for benzodiazepine 5-2-chlorophenyl) -1,2-dihydro-7-fluoro-8-methoxy-3-methylpyrazolo [3,4-b] [1,4]
LT2474545T (en)	2005-12-13	2017-02-27	Incyte Holdings Corporation	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3070090B1 (en)	2007-06-13	2018-12-12	Incyte Holdings Corporation	Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2009001884A1 (en) *	2008-10-02	2010-05-14	Incyte Holdings Corp	Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
KR20100073454A (en) *	2008-12-23	2010-07-01	국립암센터	Novel pyrazolodiazepine compound as an transglutaminase inhibitor, the preparation method thereof and a composition containing the same
UA106078C2 (en)	2009-05-22	2014-07-25	Інсайт Корпорейшн	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptanenitrile as jak inhibitors
NZ596479A (en)	2009-05-22	2014-01-31	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR078012A1 (en) *	2009-09-01	2011-10-05	Incyte Corp	HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
EA030376B1 (en) *	2010-03-10	2018-07-31	Инсайт Холдингс Корпорейшн	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2011201794A (en) *	2010-03-24	2011-10-13	Fujifilm Corp	Process for producing 5-aminopyrazole derivative and salt thereof
KR101921466B1 (en)	2010-05-21	2018-11-26	인사이트 홀딩스 코포레이션	Topical formulation for a jak inhibitor
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR20140019300A (en)	2010-11-19	2014-02-14	인사이트 코포레이션	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EA201490042A1 (en)	2011-06-20	2014-10-30	Инсайт Корпорейшн	AZETIDINYL-PHENYL-, PYRIDYL- OR PYRAZYNYLKARBOXAMID DERIVATIVES AS INHIBITORS
TW201313721A (en)	2011-08-18	2013-04-01	Incyte Corp	Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CN102603743B (en) *	2012-02-24	2014-05-28	南京天易生物科技有限公司	Anti-tumor benzazepine[f]azulene derivative, preparation method thereof, and purpose thereof
TW201406761A (en)	2012-05-18	2014-02-16	Incyte Corp	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN103626761B (en) *	2012-08-24	2015-07-29	上海医药工业研究院	Benazepine compound and the application as antitumor drug thereof
SG10202111768XA (en)	2012-11-15	2021-11-29	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
TR201820520T4 (en)	2013-03-06	2019-01-21	Incyte Holdings Corp	Processes and intermediates for making a jack inhibitor.
HUE049345T2 (en)	2013-08-07	2020-09-28	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
DK3353177T3 (en) *	2015-09-23	2020-08-24	Janssen Pharmaceutica Nv	TRICYCLIC HETEROCYCLES FOR CANCER TREATMENT
HUE057090T2 (en)	2015-09-23	2022-04-28	Janssen Pharmaceutica Nv	Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN106928040A (en) *	2015-12-31	2017-07-07	上海医药工业研究院	The preparation method of SGLT2 inhibitor intermediate
CA3046809A1 (en) *	2016-12-12	2018-06-21	The University Of Sydney	Non-peptide oxytocin receptor agonists
RU2723985C9 (en) *	2016-12-13	2020-09-21	Нанкин Транстера Биосайенсиз Ко. Лтд.	Multikinase inhibitor compound and its crystalline form and use
CN109020980B (en) *	2017-06-09	2020-11-20	华东师范大学	Pyrazolopyrimidine dinitrogen derivative with anti-tumor effect
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
RS63312B1 (en)	2018-01-30	2022-07-29	Incyte Corp	Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
BR112020019814A2 (en)	2018-03-30	2021-01-05	Incyte Corporation	TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
AR124154A1 (en)	2020-11-27	2023-02-22	Rhizen Pharmaceuticals Ag	CDK INHIBITORS
WO2022149057A1 (en)	2021-01-05	2022-07-14	Rhizen Pharmaceuticals Ag	Cdk inhibitors
WO2022236058A1 (en)	2021-05-07	2022-11-10	Kymera Therapeutics, Inc.	Cdk2 degraders and uses thereof
KR20240025485A (en)	2022-08-17	2024-02-27	한국화학연구원	Compounds for inhibiting or degrading CDK2 and/or CDK9 and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3681341A (en)	1970-12-23	1972-08-01	Hoffmann La Roche	Process for preparing 1-lower alkyl-1,4-benzodiazepin-2-ones
US5625031A (en)	1994-02-08	1997-04-29	Bristol-Myers Squibb Company	Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en)	1994-06-21	1997-05-20	The University Of Michigan	DNA encoding and 18 KD CDK6 inhibiting protein
US5733920A (en)	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
FR2741881B1 (en)	1995-12-01	1999-07-30	Centre Nat Rech Scient	NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS
US5866702A (en)	1996-08-02	1999-02-02	Cv Therapeutics, Incorporation	Purine inhibitors of cyclin dependent kinase 2
US6440959B1 (en) *	1999-04-21	2002-08-27	Hoffman-La Roche Inc.	Pyrazolobenzodiazepines

2005
- 2005-10-04 DK DK05792946T patent/DK1802625T3/en active
- 2005-10-04 NZ NZ554353A patent/NZ554353A/en not_active IP Right Cessation
- 2005-10-04 PL PL05792946T patent/PL1802625T3/en unknown
- 2005-10-04 WO PCT/EP2005/010653 patent/WO2006040036A1/en active IP Right Grant
- 2005-10-04 CA CA002582985A patent/CA2582985A1/en not_active Abandoned
- 2005-10-04 EP EP05792946A patent/EP1802625B1/en active Active
- 2005-10-04 CN CN2005800351219A patent/CN101039946B/en not_active Expired - Fee Related
- 2005-10-04 MX MX2007004464A patent/MX2007004464A/en active IP Right Grant
- 2005-10-04 RU RU2007117770/04A patent/RU2394826C2/en not_active IP Right Cessation
- 2005-10-04 DE DE602005007623T patent/DE602005007623D1/en active Active
- 2005-10-04 ES ES05792946T patent/ES2308551T3/en active Active
- 2005-10-04 CN CN2010101585349A patent/CN101899049A/en active Pending
- 2005-10-04 AU AU2005293818A patent/AU2005293818A1/en not_active Abandoned
- 2005-10-04 JP JP2007536037A patent/JP2008515939A/en active Pending
- 2005-10-04 SI SI200530331T patent/SI1802625T1/en unknown
- 2005-10-04 BR BRPI0518152-6A patent/BRPI0518152A/en not_active IP Right Cessation
- 2005-10-04 KR KR1020077008406A patent/KR100858262B1/en not_active IP Right Cessation
- 2005-10-04 AT AT05792946T patent/ATE398619T1/en active
- 2005-10-04 PT PT05792946T patent/PT1802625E/en unknown
- 2005-10-05 US US11/244,251 patent/US7524840B2/en not_active Expired - Fee Related
- 2005-10-11 AR ARP050104254A patent/AR051326A1/en not_active Application Discontinuation
- 2005-10-12 TW TW094135532A patent/TWI309652B/en not_active IP Right Cessation
2007
- 2007-04-03 NO NO20071794A patent/NO20071794L/en not_active Application Discontinuation
- 2007-04-10 IL IL182423A patent/IL182423A0/en unknown
- 2007-04-11 ZA ZA200702973A patent/ZA200702973B/en unknown
2008
- 2008-02-28 HK HK08102254.9A patent/HK1108284A1/en not_active IP Right Cessation
- 2008-09-03 HR HR20080429T patent/HRP20080429T3/en unknown

Also Published As

Publication number	Publication date
TW200628469A (en)	2006-08-16
CA2582985A1 (en)	2006-04-20
AR051326A1 (en)	2007-01-03
ATE398619T1 (en)	2008-07-15
NZ554353A (en)	2010-01-29
NO20071794L (en)	2007-07-10
DE602005007623D1 (en)	2008-07-31
ZA200702973B (en)	2009-09-30
AU2005293818A1 (en)	2006-04-20
EP1802625A1 (en)	2007-07-04
PT1802625E (en)	2008-08-06
CN101039946B (en)	2010-12-08
CN101899049A (en)	2010-12-01
RU2007117770A (en)	2008-11-20
KR100858262B1 (en)	2008-09-11
JP2008515939A (en)	2008-05-15
HRP20080429T3 (en)	2008-09-30
MX2007004464A (en)	2007-05-07
CN101039946A (en)	2007-09-19
TWI309652B (en)	2009-05-11
BRPI0518152A (en)	2008-11-04
EP1802625B1 (en)	2008-06-18
IL182423A0 (en)	2007-07-24
PL1802625T3 (en)	2008-12-31
RU2394826C2 (en)	2010-07-20
US7524840B2 (en)	2009-04-28
KR20070054243A (en)	2007-05-28
US20060079511A1 (en)	2006-04-13
ES2308551T3 (en)	2008-12-01
HK1108284A1 (en)	2008-05-02
SI1802625T1 (en)	2008-10-31
WO2006040036A1 (en)	2006-04-20

Publication	Publication Date	Title
DK1802625T3 (en)	2008-09-01	Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer
NL301145I2 (en)	2021-12-07	Tirbanibulin
NO2017019I1 (en)	2017-05-04	Diarylhydantoin compound, pharmaceutical composition and use thereof
DK1960370T3 (en)	2012-01-02	Pyridazinone derivatives for tumor treatment
CL2008001234A1 (en)	2008-09-22	COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF APOPTOSIS PROTEINS; AND USE IN THE TREATMENT OF CANCER.
NO20053403D0 (en)	2005-07-13	Process for treating ground formations and fluids for this mill.
DK2155188T3 (en)	2013-11-04	Methods and compositions for the treatment of recurrent cancer
DK2139483T3 (en)	2014-01-13	Combination therapies including a quinoxaline inhibitor of PI3K-alpha for use in the treatment of cancer
DK2195015T3 (en)	2017-06-19	Composition for the treatment of prostate cancer
EA200900091A1 (en)	2009-06-30	NEW INDICATIONS FOR THE USE OF DIRECT THROMBIN INHIBITORS IN THE TREATMENT OF CARDIOVASCULAR DISEASES
DK1885380T3 (en)	2012-10-22	Sodium metaarsenite for use in the treatment of metastatic neoplastic diseases
DK2340042T3 (en)	2014-10-27	Methods and Preparations for the Treatment of Cancer
NO20080622L (en)	2008-03-26	Disycloalkylurea glucokinase activators
DK2342233T3 (en)	2014-09-29	Anti-CXCR4 antibodies and their use in the treatment of cancer
DK1749098T3 (en)	2011-04-04	Chimeric adenoviruses for use in cancer treatment
FR2872704B1 (en)	2007-11-02	PLURITHERAPY AGAINST CANCER
DK2235002T3 (en)	2013-03-11	4-pyridinone compounds and their use in the treatment of cancer
EA201071248A1 (en)	2011-06-30	DESIGNED PHTHALASINE ANTAGONISTS WAYS HEDGEHOG
NO20055686L (en)	2007-06-04	Composition, method of preparation thereof, and use thereof.
IS8125A (en)	2005-11-11	Quinazoline derivatives for the treatment of cancer
NO20093542L (en)	2010-02-12	Inhibition of tumor metastasis by anti-neuropilin 2 antibodies
DE602006013009D1 (en)	2010-04-29	PHARMACEUTICAL COMPOSITION OF MAHANINE FOR THE TREATMENT OF PROSTATE CANCER
DK1611890T3 (en)	2009-11-16	Method for evaluation and treatment of cancer
EA200971067A1 (en)	2010-04-30	TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
ITMI20051107A1 (en)	2005-09-13	METHOD FOR CANCER TREATMENT